UPDATE: Stifel Nicolaus Initiates Oncothyreon at Buy with $10 PT on Stimuvax Outlook

Stifel Nicolaus initiated coverage on Oncothyreon ONTY with a Buy rating and a price target of $10. Stifel Nicolaus commented, "Stimuvax success would provide significant upside potential while emerging pipeline gives downside protection. Lead compound Stimuvax is approaching completion in a large Phase III study for non-small cell lung cancer (NSCLC), with final data by partner Merck KGaA likely in 1Q13. We anticipate this will be a classic biotech binary event, with potential to transform treatment of disease if results are positive, and potential for stock price volatility from now through the data read-out." Oncothyreon closed at $4.47 on Thursday.